Drive Wealth Management LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,700 shares of the medical equipment provider’s stock, valued at approximately $554,000.
A number of other hedge funds also recently added to or reduced their stakes in BSX. Perigon Wealth Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $883,000. Y Intercept Hong Kong Ltd boosted its stake in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC purchased a new stake in Boston Scientific during the 2nd quarter worth approximately $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab grew its position in Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in Boston Scientific during the 2nd quarter worth approximately $38,539,000. 89.07% of the stock is owned by hedge funds and other institutional investors.
Boston Scientific Price Performance
Shares of NYSE BSX opened at $44.33 on Monday. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $104.61. The business’s 50 day moving average price is $44.00 and its 200 day moving average price is $54.50. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. The firm has a market cap of $64.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 1.31 and a beta of 0.60.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the firm posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on BSX shares. Argus cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, July 31st. TD Cowen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $56.00 to $46.00 in a research note on Friday, October 30th. Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, October 29th. Canaccord Genuity Group cut their target price on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Finally, Sanford C. Bernstein reduced their target price on Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $61.43.
View Our Latest Analysis on Boston Scientific
Boston Scientific Company Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Featured Stories
- Five stocks we like better than Boston Scientific
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
